Search:
Tokushima UniversityInstitute of Advanced Medical Sciences重点研究部門
Tokushima UniversityGraduate School of MedicineMedicineMolecular Medicine
Tokushima UniversityResearch ClustersResearch Clusters (Specified)2001004 統合的がん研究創薬クラスター∼多段階発がん関連分子を標的とした中分子創薬の開発∼
(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Personal Web Page

Field of Study

Medicine

Subject of Study

Book / Paper

Book:

1. Tetsuro Yoshimaru and Toyomasa Katagiri :
乳がんにおける新規がん抑制因子不活化機構の解明と創薬研究,
Sep. 2018.

Academic Paper (Judged Full Paper):

1. Shun-ichi Toki, Tetsuro Yoshimaru, Yosuke Matsushita, Hitoshi Aibara, Masaya Ono, Koichi Tsuneyama, Koichi Sairyo and Toyomasa Katagiri :
The survival and proliferation of osteosarcoma cells are dependent on the mitochondrial BIG3-PHB2 complex formation.,
Cancer Science, Vol.112, No.10, 4208-4219, 2021.
(Tokushima University Institutional Repository: 116580,   DOI: 10.1111/cas.15099,   PubMed: 34363714)
2. Tetsuro Yoshimaru, Yusuke Nakamura and Toyomasa Katagiri :
Functional genomics for breast cancer drug target discovery.,
Journal of Human Genetics, Vol.66, No.9, 927-935, 2021.
(Tokushima University Institutional Repository: 117231,   DOI: 10.1038/s10038-021-00962-6,   PubMed: 34285339)
3. Ryuichiro Kimura, Tetsuro Yoshimaru, Yosuke Matsushita, Taisuke Matsuo, Masaya Ono, Jae-Hyun Park, Mitsunori Sasa, Yasuo Miyoshi, Yusuke Nakamura and Toyomasa Katagiri :
The GALNT6‑LGALS3BP axis promotes breast cancer cell growth.,
International Journal of Oncology, Vol.56, No.2, 581-595, 2019.
(DOI: 10.3892/ijo.2019.4941,   PubMed: 31894262)
4. Takeru Chigira, Satoru Nagatoishi, Hiroyuki Takeda, Tetsuro Yoshimaru, Toyomasa Katagiri and Kouhei Tsumoto :
Biophysical characterization of the breast cancer-related BIG3-PHB2 interaction: Effect of non-conserved loop region of BIG3 on the structure and the interaction.,
Biochemical and Biophysical Research Communications, Vol.518, No.1, 183-189, 2019.
(DOI: 10.1016/j.bbrc.2019.08.028,   PubMed: 31421830)
5. Kei Daizumoto, Tetsuro Yoshimaru, Yosuke Matsushita, Tomoya Fukawa, Hisanori Uehara, Masaya Ono, Masato Komatsu, Hiro-omi Kanayama and Toyomasa Katagiri :
A DDX31/mutant-p53/EGFR axis promotes multistep progression of muscle invasive bladder cancer,
Cancer Research, Vol.78, No.9, 2233-2247, 2018.
(Tokushima University Institutional Repository: 111804,   DOI: 10.1158/0008-5472.CAN-17-2528,   PubMed: 29440146)
6. Yoshimasa Miyagawa, Yosuke Matsushita, Hiromu Suzuki, Masato Komatsu, Tetsuro Yoshimaru, Ryuichiro Kimura, Ayako Yanai, Junko Honda, Akira Tangoku, Mitsunori Sasa, Yasuo Miyoshi and Toyomasa Katagiri :
Frequent downregulation of LRRC26 by epigenetic alterations is involved in the malignant progression of triple-negative breast cancer.,
International Journal of Oncology, 2018.
(DOI: 10.3892/ijo.2018.4301,   PubMed: 29512727)
7. Tetsuro Yoshimaru, Masaya Ono, Yoshimi Bando, Yi-An Chen, Kenji Mizuguchi, Hiroshi Shima, Masato Komatsu, Issei Imoto, Keisuke Izumi, Junko Honda, Yasuo Miyoshi, Mitsunori Sasa and Toyomasa Katagiri :
A-kinase anchoring protein BIG3 coordinates oestrogen signalling in breast cancer cells.,
Nature Communications, Vol.8, No.15427, 2017.
(Tokushima University Institutional Repository: 112449,   DOI: 10.1038/ncomms15427,   PubMed: 28555617,   Elsevier: Scopus)
8. Tetsuro Yoshimaru, Keisuke Aihara, Masato Komatsu, Yosuke Matsushita, Yasumasa Okazaki, Shinya Toyokuni, Junko Honda, Mitsunori Sasa, Yasuo Miyoshi, Akira Otaka and Toyomasa Katagiri :
Stapled BIG3 helical peptide ERAP potentiates anti-tumour activity for breast cancer therapeutics.,
Scientific Reports, Vol.7, No.1, 1821, 2017.
(Tokushima University Institutional Repository: 112387,   DOI: 10.1038/s41598-017-01951-6,   PubMed: 28500289)
9. Yuki Shikata, Tetsuro Yoshimaru, Masato Komatsu, Hiroto Katoh, Reiko Sato, Shuhei Kanagaki, Yasumasa Okazaki, Shinya Toyokuni, Etsu Tashiro, Shumpei Ishikawa, Toyomasa Katagiri and Masaya Imoto :
Protein kinase A inhibition facilitates the antitumor activity of xanthohumol, a valosin-containing protein inhibitor.,
Cancer Science, Vol.108, No.4, 785-794, 2017.
(Tokushima University Institutional Repository: 112374,   DOI: 10.1111/cas.13175,   PubMed: 28122154)
10. Namhee Kim, Tetsuro Yoshimaru, Yi-An Chen, Taisuke Matsuo, Masato Komatsu, Yasuo Miyoshi, Eiji Tanaka, Mitsunori Sasa, Kenji Mizuguchi and Toyomasa Katagiri :
BIG3 Inhibits the Estrogen-Dependent Nuclear Translocation of PHB2 via Multiple Karyopherin-Alpha Proteins in Breast Cancer Cells.,
PLoS ONE, Vol.10, No.6, 2015.
(Tokushima University Institutional Repository: 109497,   DOI: 10.1371/journal.pone.0127707,   PubMed: 26052702,   Elsevier: Scopus)
11. Tetsuro Yoshimaru, Masato Komatsu, Yasuo Miyoshi, Junko Honda, Mitsunori Sasa and Toyomasa Katagiri :
Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer.,
Cancer Science, Vol.106, No.5, 550-558, 2015.
(DOI: 10.1111/cas.12654,   PubMed: 25736224,   Elsevier: Scopus)
12. Tetsuro Yoshimaru, Masato Komatsu, Etsu Tashiro, Masaya Imoto, Hiroyuki Osada, Yasuo Miyoshi, Junko Honda, Mitsunoi Sasa and Toyomasa Katagiri :
Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions.,
Scientific Reports, Vol.4, 7355, 2014.
(DOI: 10.1038/srep07355,   PubMed: 25483453)
13. Taisuke Matsuo, Le Tan Dat, Masato Komatsu, Tetsuro Yoshimaru, Kei Daizumoto, Saburo Sone, Yasuhiko Nishioka and Toyomasa Katagiri :
Early growth response 4 is involved in cell proliferation of small cell lung cancer through transcriptional activation of its downstream genes.,
PLoS ONE, Vol.9, No.11, e113606, 2014.
(DOI: 10.1371/journal.pone.0113606,   PubMed: 25411851,   Elsevier: Scopus)
14. Yi-An Chen, Yoichi Murakami, Shandar Ahmad, Tetsuro Yoshimaru, Toyomasa Katagiri and Kenji Mizuguchi :
Brefeldin A-inhibited guanine nucleotide-exchange protein 3 (BIG3) is predicted to interact with its partner through an ARM-type -helical structure.,
BMC Research Notes, Vol.7, No.1, 435, 2014.
(Tokushima University Institutional Repository: 114782,   DOI: 10.1186/1756-0500-7-435,   PubMed: 24997568)
15. Taisuke Matsuo, Masato Komatsu, Tetsuro Yoshimaru, Kazuma Kiyotani, Yasuo Miyoshi, Mitsunori Sasa and Toyomasa Katagiri :
Involvement of B3GALNT2 overexpression in the cell growth of breast cancer.,
International Journal of Oncology, Vol.44, No.2, 427-434, 2013.
(DOI: 10.3892/ijo.2013.2187,   PubMed: 24285400,   Elsevier: Scopus)
16. Masato Komatsu, Tetsuro Yoshimaru, Taisuke Matsuo, Kazuma Kiyotani, Yasuo Miyoshi, Toshihito Tanahashi, Kazuhito Rokutan, Rui Yamaguchi, Ayumu Saito, Seiya Imoto, Satoru Miyano, Yusuke Nakamura, Mitsunori Sasa, Mitsuo Shimada and Toyomasa Katagiri :
Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis.,
International Journal of Oncology, Vol.42, No.2, 478-506, 2013.
(DOI: 10.3892/ijo.2012.1744,   PubMed: 23254957)
17. Tetsuro Yoshimaru, Masato Komatsu, Taisuke Matsuo, Yi-An Chen, Yoichi Murakami, Kenji Mizuguchi, Eiichi Mizohata, Tsuyoshi Inoue, Miki Akiyama, Rui Yamaguchi, Seiya Imoto, Satoru Miyano, Yasuo Miyoshi, Mitsunori Sasa, Yusuke Nakamura and Toyomasa Katagiri :
Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells.,
Nature Communications, Vol.4, 2443, 2013.
(DOI: 10.1038/ncomms3443,   PubMed: 24051437)
18. Le T Dat, Taisuke Matsuo, Tetsuro Yoshimaru, Souji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi, Takuya Kuramoto, Yasuhiko Nishioka, Saburo Sone and Toyomasa Katagiri :
Identification of genes potentially involved in bone metastasis by genome-wide gene expression profile analysis of non-small cell lung cancer in mice,
International Journal of Oncology, Vol.40, No.5, 1455-1469, 2012.
(DOI: 10.3892/ijo.2012.1348,   PubMed: 22294041)
19. Satoshi Nunomura, Yasuhiro Gon, Tetsuro Yoshimaru, Junichi Kashiwakura, Toshiaki Kawakami and Chisei Ra :
FcepsilonRI beta-chain ITAM amplifies PI3K-signaling to ensure synergistic degranulation response via FcepsilonRI and adenosine receptors.,
European Journal of Immunology, Vol.40, No.4, 1205-1217, 2010.
(DOI: 10.1002/eji.200939651,   PubMed: 20101614)
20. Toshio Inoue, Yoshihiro Suzuki, Kazuya Mizuno, Kazuko Nakata, Tetsuro Yoshimaru and Chisei Ra :
SHP-1 exhibits a pro-apoptotic function in antigen-stimulated mast cells: positive regulation of mitochondrial death pathways and negative regulation of survival signaling pathways.,
Molecular Immunology, Vol.47, No.2-3, 222-232, 2009.
(DOI: 10.1016/j.molimm.2009.09.033,   PubMed: 19875169)
21. Toshio Inoue, Yoshihiro Suzuki, Tetsuro Yoshimaru and Chisei Ra :
Nitric Oxide positively regulates Ag (I)-induced Ca(2+) influx and mast cell activation: role of a Nitric Oxide Synthase-independent pathway.,
Journal of Leukocyte Biology, Vol.86, No.6, 1365-1375, 2009.
(DOI: 10.1189/jlb.0609387,   PubMed: 19706839)
22. Yoshihiro Suzuki, Tetsuro Yoshimaru, Toshio Inoue and Chisei Ra :
Discrete generations of intracellular hydrogen peroxide and superoxide in antigen-stimulated mast cells: reciprocal regulation of store-operated Ca2+ channel activity.,
Molecular Immunology, Vol.46, No.11-12, 2200-2209, 2009.
(DOI: 10.1016/j.molimm.2009.04.013,   PubMed: 19467708)
23. Yoshihiro Suzuki, Tetsuro Yoshimaru, Toshio Inoue and Chisei Ra :
Ca v 1.2 L-type Ca2+ channel protects mast cells against activation-induced cell death by preventing mitochondrial integrity disruption.,
Molecular Immunology, Vol.46, No.11-12, 2370-2380, 2009.
(DOI: 10.1016/j.molimm.2009.03.017,   PubMed: 19447492)
24. Toshio Inoue, Yoshihiro Suzuki, Tetsuro Yoshimaru and Chisei Ra :
Ca2+-dependent mast cell death induced by Ag (I) via cardiolipin oxidation and ATP depletion.,
Journal of Leukocyte Biology, Vol.86, No.1, 167-179, 2009.
(DOI: 10.1189/jlb.1108691,   PubMed: 19401388)
25. Kana Togo, Yoshihiro Suzuki, Tetsuro Yoshimaru, Toshio Inoue, Tadashi Terui, Toyoko Ochiai and Chisei Ra :
Aspirin and salicylates modulate IgE-mediated leukotriene secretion in mast cells through a dihydropyridine receptor-mediated Ca(2+) influx.,
Clinical Immunology, Vol.131, No.1, 145-156, 2009.
(DOI: 10.1016/j.clim.2008.09.008,   PubMed: 19144570)
26. Tetsuro Yoshimaru, Yoshihiro Suzuki, Toshio Inoue and Chisei Ra :
L-type Ca2+ channels in mast cells: activation by membrane depolarization and distinct roles in regulating mediator release from store-operated Ca2+ channels.,
Molecular Immunology, Vol.46, No.7, 1267-1277, 2009.
(DOI: 10.1016/j.molimm.2008.11.011,   PubMed: 19128833)
27. Kazuko Nakata, Tetsuro Yoshimaru, Yoshihiro Suzuki, Toshio Inoue, Chisei Ra, Hidetaka Yakura and Kazuya Mizuno :
Positive and negative regulation of high affinity IgE receptor signaling by Src homology region 2 domain-containing phosphatase 1.,
The Journal of Immunology, Vol.181, No.8, 5414-5424, 2008.
(PubMed: 18832698,   Elsevier: Scopus)
28. Tetsuro Yoshimaru, Yoshihiro Suzuki, Toshio Inoue, Shigeru Nishida and Chisei Ra :
Extracellular superoxide released from mitochondria mediates mast cell death by advanced glycation end products.,
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, Vol.1783, No.12, 2332-2343, 2008.
(DOI: 10.1016/j.bbamcr.2008.08.010,   PubMed: 18822320)
29. Takashi Matsui, Satoshi Nunomura, Toshibumi Shimokawa, Tetsuro Yoshimaru and Chisei Ra :
Functionality of the IgA Fc receptor (FcalphaR, CD89) is down-regulated by extensive engagement of FcepsilonRI.,
Clinical Immunology, Vol.129, No.1, 155-162, 2008.
(DOI: 10.1016/j.clim.2008.07.003,   PubMed: 18700185)
30. Satoshi Nunomura, Tetsuro Yoshimaru and Chisei Ra :
Na-Tosyl-Phe chloromethyl ketone prevents granule movement and mast cell synergistic degranulation elicited by costimulation of antigen and adenosine.,
Life Sciences, Vol.83, No.7-8, 242-249, 2008.
(DOI: 10.1016/j.lfs.2008.06.015,   PubMed: 18634805)
31. Toshio Inoue, Yoshihiro Suzuki, Tetsuro Yoshimaru and Chisei Ra :
Nitric oxide protects mast cells from activation-induced cell death: the role of the phosphatidylinositol-3 kinase-Akt-endothelial nitric oxide synthase pathway.,
Journal of Leukocyte Biology, Vol.83, No.5, 1218-1229, 2008.
(DOI: 10.1189/jlb.1007667,   PubMed: 18285401)
32. Yoshihiro Suzuki, Toshio Inoue, Tetsuro Yoshimaru and Chisei Ra :
Galectin-3 but not galectin-1 induces mast cell death by oxidative stress and mitochondrial permeability transition.,
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, Vol.1783, No.5, 924-934, 2008.
(DOI: 10.1016/j.bbamcr.2008.01.025,   PubMed: 18302939)
33. Yoshihiro Suzuki, Tetsuro Yoshimaru, Toshio Inoue, Satoshi Nunomura and Chisei Ra :
The high-affinity immunoglobulin E receptor (FcepsilonRI) regulates mitochondrial calcium uptake and a dihydropyridine receptor-mediated calcium influx in mast cells: Role of the FcepsilonRIbeta chain immunoreceptor tyrosine-based activation motif.,
Biochemical Pharmacology, Vol.75, No.7, 1492-1503, 2007.
(DOI: 10.1016/j.bcp.2007.12.006,   PubMed: 18243160)
34. Toshio Inoue, Yoshihiro Suzuki, Tetsuro Yoshimaru and Chisei Ra :
Reactive oxygen species produced up- or downstream of calcium influx regulate proinflammatory mediator release from mast cells: role of NADPH oxidase and mitochondria.,
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, Vol.1783, No.5, 789-802, 2007.
(DOI: 10.1016/j.bbamcr.2007.12.004,   PubMed: 18178162)
35. Tetsuro Yoshimaru, Yoshihiro Suzuki, Toshio Inoue, Osamu Niide and Chisei Ra :
Silver activates mast cells through reactive oxygen species production and a thiol-sensitive store-independent Ca2+ influx.,
Free Radical Biology and Medicine, Vol.40, No.11, 1949-1959, 2006.
(DOI: 10.1016/j.freeradbiomed.2006.01.023,   PubMed: 16716896)
36. Yoshihiro Suzuki, Tetsuro Yoshimaru, Toshio Inoue and Chisei Ra :
Mitochondrial Ca2+ flux is a critical determinant of the Ca2+ dependence of mast cell degranulation.,
Journal of Leukocyte Biology, Vol.79, No.3, 508-518, 2005.
(DOI: 10.1189/jlb.0705412,   PubMed: 16365155)
37. Osamu Niide, Yoshihiro Suzuki, Tetsuro Yoshimaru, Toshio Inoue, Tadatoshi Takayama and Chisei Ra :
Fungal metabolite gliotoxin blocks mast cell activation by a calcium- and superoxide-dependent mechanism: implications for immunosuppressive activities.,
Clinical Immunology, Vol.118, No.1, 108-116, 2005.
(DOI: 10.1016/j.clim.2005.08.012,   PubMed: 16213796)
38. Satoshi Nunomura, Yasuhiro Gon, Tetsuro Yoshimaru, Yoshihiro Suzuki, Hajime Nishimoto, Toshiaki Kawakami and Chisei Ra :
Role of the FcepsilonRI beta-chain ITAM as a signal regulator for mast cell activation with monomeric IgE.,
International Immunology, Vol.17, No.6, 685-694, 2005.
(DOI: 10.1093/intimm/dxh248,   PubMed: 15944196)
39. T Suda, Y Suzuki, T Matsui, T Inoue, O Niide, Tetsuro Yoshimaru, H Suzuki, C Ra and T Ochiai :
Dapsone suppresses human neutrophil superoxide production and elastase release in a calcium-dependent manner.,
The British Journal of Dermatology, Vol.152, No.5, 887-895, 2005.
(DOI: 10.1111/j.1365-2133.2005.06559.x,   PubMed: 15888142)
40. Yoshihiro Suzuki, Tetsuro Yoshimaru, Takashi Matsui, Toshio Inoue, Osamu Niide, Satoshi Nunomura and Chisei Ra :
Fc epsilon RI signaling of mast cells activates intracellular production of hydrogen peroxide: role in the regulation of calcium signals.,
The Journal of Immunology, Vol.171, No.11, 6119-6127, 2003.
(PubMed: 14634127)
41. Yoshihiro Suzuki, Tetsuro Yoshimaru, Takashi Matsui and Chisei Ra :
Silver activates calcium signals in rat basophilic leukemia-2H3 mast cells by a mechanism that differs from the Fc epsilon RI-activated response.,
The Journal of Immunology, Vol.169, No.7, 3954-3962, 2002.
(PubMed: 12244196)
42. Tetsuro Yoshimaru, Y Suzuki, T Matsui, K Yamashita, T Ochiai, M Yamaki and K Shimizu :
Blockade of superoxide generation prevents high-affinity immunoglobulin E receptor-mediated release of allergic mediators by rat mast cell line and human basophils.,
Clinical and Experimental Allergy, Vol.32, No.4, 612-618, 2002.
(DOI: 10.1046/j.0954-7894.2002.01263.x,   PubMed: 11972610)
43. Y Suzuki, Tetsuro Yoshimaru, K Yamashita, T Matsui, M Yamaki and K Shimizu :
Exposure of RBL-2H3 mast cells to Ag(+) induces cell degranulation and mediator release.,
Biochemical and Biophysical Research Communications, Vol.283, No.3, 707-714, 2001.
(DOI: 10.1006/bbrc.2001.4844,   PubMed: 11341783)
44. T Matsui, Y Suzuki, K Yamashita, Tetsuro Yoshimaru, M Suzuki-Karasaki, S Hayakawa, M Yamaki and K Shimizu :
Diphenyleneiodonium prevents reactive oxygen species generation, tyrosine phosphorylation, and histamine release in RBL-2H3 mast cells.,
Biochemical and Biophysical Research Communications, Vol.276, No.2, 742-748, 2000.
(DOI: 10.1006/bbrc.2000.3545,   PubMed: 11027541)
45. K Yamashita, Y Suzuki, T Matsui, Tetsuro Yoshimaru, M Yamaki, M Suzuki-Karasaki, S Hayakawa and K Shimizu :
Epigallocatechin gallate inhibits histamine release from rat basophilic leukemia (RBL-2H3) cells: role of tyrosine phosphorylation pathway.,
Biochemical and Biophysical Research Communications, Vol.274, No.3, 603-608, 2000.
(DOI: 10.1006/bbrc.2000.3200,   PubMed: 10924324)

Academic Paper (Unrefereed Paper):

1. Keitaroh Anyohji, Keisuke Aihara, Tetsuro Yoshimaru, Akira Shigenaga, Toyomasa Katagiri and Akira Otaka :
Development of anti-cancer peptide based on prohibitin 2,
Peptide Science 2018, 46, 2019.

Review, Commentary:

1. Tetsuro Yoshimaru and Toyomasa Katagiri :
Targeting BIG3-PHB2 interaction potentiates an effective therapy for hormone-dependent breast cancer,
The Medical Frontline, Vol.74, No.5, 115-121, 2019.
2. Tetsuro Yoshimaru, Yosuke Matsushita and Toyomasa Katagiri :
Elucidating Molecular-mechanism of Triple-negative Breast Cancer Through Comprehensive Genome Analysis,
Japanese Journal of Breast Cancer, Vol.31, No.5, 377-385, Oct. 2016.
3. Tetsuro Yoshimaru, Yosuke Matsushita and Toyomasa Katagiri :
Elucidating Molecular-mechanism of Triple-negative Breast Cancer Through Comprehensive Genome Analysis,
Japanese Journal of Breast Cancer, Vol.31, No.5, 377-385, Oct. 2016.
4. Yoshihiro Suzuki, Tetsuro Yoshimaru, Toshio Inoue, Osamu Niide and Chisei Ra :
Role of oxidants in mast cell activation.,
Chemical Immunology and Allergy, Vol.87, 32-42, 2005.
(DOI: 10.1159/000087569,   PubMed: 16107761)

Proceeding of International Conference:

1. Tetsuro Yoshimaru, Yosuke Matsushita, Sasa Mitsunori, Miyoshi Yasuo and Toyomasa Katagiri :
BIG3 phosphatase inactivates tumor suppressor PHB2 via tis dephosphorylation to contribute to the breast carcinogenesis,
The 14th International Conference on Protein Phosphatase, Online, Dec. 2020.
2. Yosuke Matsushita, Masato Komatsu, Kazuma Kiyotani, Tetsuro Yoshimaru, Suzuki Hiromu, Miyoshi Yasuo, Sasa Mitsunori and Toyomasa Katagiri :
Frequent downregulation of SALL3 by genetic and epigenetic alterations is involved in progression and chemoresistance of triple negative breast cancers,
American Association for Cancer Research ANNUAL MEETING 2019, Atlanta, Apr. 2019.
3. Tetsuro Yoshimaru, Yosuke Matsushita, Sasa Mitsunori, Miyoshi Yasuo and Toyomasa Katagiri :
PHB2 inactivation by AKAP-BIG3 is required for progression of HER2-overexpressing breast cancer,
American Association for Cancer Research ANNUAL MEETING 2019, Atlanta, Apr. 2019.
4. Keitaroh Anyohji, Keisuke Aihara, Tetsuro Yoshimaru, Akira Shigenaga, Toyomasa Katagiri and Akira Otaka :
Development of anti-cancer peptide based on prohibitin 2,
10th International Peptide Symposium, Kyoto, Dec. 2018.
5. Yosuke Matsushita, Masato Komatsu, Kazuma Kiyotani, Tetsuro Yoshimaru, Suzuki Hiromu, Miyoshi Yasuo, Sasa Mitsunori and Toyomasa Katagiri :
Frequent downregulation of SALL3 by recurrent genetic and epigenetic alterations is involved in triple-negative breast cancers,
American Association for Cancer Research ANNUAL MEETING 2018, Vol.78, No.13, Chicago, Apr. 2018.
(DOI: 10.1158/1538-7445.AM2018-5315)
6. Tetsuro Yoshimaru, Yosuke Matsushita, Sasa Mitsunori, Miyoshi Yasuo and Toyomasa Katagiri :
Overcoming trastuzumab resistance in HER2-overexpressing breast cancer by utilizing PHB2, a tumor suppressor of multiple resistance pathways,
American Association for Cancer Research ANNUAL MEETING 2018, Chicago, Apr. 2018.
7. Toyomasa Katagiri, Kei Daizumoto, Tetsuro Yoshimaru, Yosuke Matsushita, Tomoya Fukawa, Ono Masaya and Hiro-omi Kanayama :
DDX31 cooperates with mutant p53 and EGFR to promote the multistep progression of invasive bladder cancer,
American Association For Cancer Research ANNUAL MEETING 2018, Chicago, Apr. 2018.
8. Akira Otaka, Keisuke Aihara, Tetsuro Yoshimaru, Akira Shigenaga and Toyomasa Katagiri :
Development of long-lasting stapled peptides targeting BIG3-PHB2 interaction in breast cancer cells,
The 6th Pharmaceutical Sciences World Congress 2017, Stockholm, May 2017.
9. Tetsuro Yoshimaru and Toyomasa Katagiri :
Development of chemically modified peptide inhibitor ERAP targeting BIG3-PHB2 complex on hormone-resistant breast cancer,
2nd International Symposium of Molecular Medicine in Tokushima University, Tokushima, Nov. 2016.
10. Tetsuro Yoshimaru, Ono Masaya, Mizuguchi Kenji, Miyoshi Yasuo, Mitsunori Sasa and Toyomasa Katagiri :
A novel A-kinase anchoring protein BIG3, coordinates estrogen signalling in breast cancer cells,
The 12th International Conference on Protein Phosphatase, Oct. 2016.
11. Toyomasa Katagiri, Tetsuro Yoshimaru, Masato Komatsu and Taisuke Matsuo :
BIG3-PHB2 Interaction is a key therapeutic target in Iuminal-type of breast cancer.,
Amerian Association for Cancer Research (AACR) Annal Meeting 2014, San Diego, Apr. 2014.
12. Taisuke Matsuo, Ono Masaya, Tetsuro Yoshimaru, Miyoshi Yasuo, Sasa Mitsunori, Nakamura Yusuke and Toyomasa Katagiri :
Functional roles of a novel glycosyltrasnferase BCGT1 in breast cancer cells,
70th Annual Meeting of the Japanese Cancer Association, Oct. 2011.
13. Tetsuro Yoshimaru, Komatsu Masato, Taisuke Matsuo, Miyoshi Yasuo, Sasa Mitsunori, Nakamura Yusuke and Toyomasa Katagiri :
Novel modeling of ER signaling regulation in E2-dependent breast cancer - New therapeutic target for ERAP1-REA complex,
70th Annual Meeting of the Japanese Cancer Association, Oct. 2011.
14. Toyomasa Katagiri, Tetsuro Yoshimaru, Taisuke Matsuo, 三好 康雄, 笹 三徳 and 中村 祐輔 :
Novel mechanism for activation of estrogen/estrogen-receptor signaling and novel therapeutic strategies in breast cancer,
69th Annual Meeting of the Japanese Cancer Association, Sep. 2010.
15. Taisuke Matsuo, Tetsuro Yoshimaru, 三好 康雄, 笹 三徳, 中村 祐輔 and Toyomasa Katagiri :
Identification and characterization of BCGT1 as a novel molecular target for breast cancer therapy,
69th Annual Meeting of the Lapanese Cancer Association, Osaka, Sep. 2010.
16. Tetsuro Yoshimaru, Taisuke Matsuo, Miyoshi Yasuo, Sasa Mitsunori, Nakamura Yusuke and Toyomasa Katagiri :
Elucidating molecular-mechanism of triple-negative breast cancer through genome-wide gene-expression profile analysis,
69th Annual Meeting of the Japanese Cancer Association, Osaka, Sep. 2010.
17. Toyomasa Katagiri, Tetsuro Yoshimaru, Taisuke Matsuo, Miyoshi Yasuo, Sasa Mitsunori and Nakamura Yusuke :
Critical role of transactivation of ERAP1,estrogen receptor activity-regulated protein 1, in estrogen-dependent breast cancer cell growth,
The 6th International Symposium on Hormonal Carcinogenesisi in Japan, Sep. 2010.
18. Tetsuro Yoshimaru, Suzuki Yoshihiro, Inoue Toshio, Nunomura Satoshi and Ra Chisei :
Mitochondria calcium flux via the FcepsilonRI beta is critical for calcium mobilization and mast cell activation.,
Jun. 2006.
19. Tetsuro Yoshimaru, Suzuki Yoshihiro, Niide Osamu, Inoue Toshio, Matsui Takashi and Ra Chisei :
Heavy metals activate mast cells by an oxidant-dependent mechanism: role of redox-sensitive noncapacitative calcium influx.,
Oct. 2004.
20. Tetsuro Yoshimaru, Suzuki Yoshihiro, Inoue Toshio, Matsui Takashi, Niide Osamu and Ra Chisei :
Heavy metals activate mast cells by an oxidant-dependent mechanism: role of redox-sensitive noncapacitative calcium influx.,
Jul. 2004.
21. Tetsuro Yoshimaru, Suzuki Yoshihiro, Yamaki Mitsuo, Ra Chisei and Shimizu Kazufumi :
Silver nitrate activates mast cells: Distinctions from FcRI-induced activation.,
Nov. 2001.
22. Tetsuro Yoshimaru, Suzuki Yoshihiro, Yamashita Kohei, Matsui Takashi, Yamaki Mitsuo and Shimizu Kazufumi :
Role of reactive oxygen species in the high affinity IgE receptor-mediated intracellular signaling to degranulation and mediator.,
Jul. 2001.
23. Tetsuro Yoshimaru, Matsui Toshiro, Matsumoto Kiyoshi and Osajima Yutaka :
Preparation of Microencapsulated Enzyme for Lowering Allergic Activity of Food.,
Nov. 1996.

Proceeding of Domestic Conference:

1. Keiji Uchiyama, Tetsuro Yoshimaru, Yosuke Matsushita, 尾野 雅哉, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
乳がん細胞における O型糖鎖修飾を介した IRE1の恒常的活性化機構,
第95回日本生化学会大会, Nov. 2022.
2. Yosuke Matsushita, Kazumasa Okumura, Masato Komatsu, Tetsuro Yoshimaru, Ono Masaya, Akira Tangoku, Miyoshi Yasuo, Sasa Mitsunori and Toyomasa Katagiri :
RHBDL2 has essential roles for glutaminolysis and chemoresistance in triple negative breast cancer,
The 17th International Symposium of the Institute Network for Biomedical Sciences International Symposium on Tumor Biology in Kanazawa 2022, Oct. 2022.
3. Tetsuro Yoshimaru, Yosuke Matsushita, Hidetaka Kosako, Sasa Mitsunorii, Miyoshi Yasuo and Toyomasa Katagiri :
The plasma membrane BIG3-PHB2 complex contributes to the acquisition of trastuzumab-resistance in HER2-positive breast cancer,
The 17th International Symposium of the Institute Network for Biomedical Sciences International Symposium on Tumor Biology in Kanazawa 2022, Oct. 2022.
4. HAGIWARA Kosei, Keiji Uchiyama, Tetsuro Yoshimaru, Yosuke Matsushita, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
乳がん細胞におけるO 結合型糖鎖修飾GRP78/Bip の役割解明と創薬研究,
第81回日本癌学会学術総会, Oct. 2022.
5. Hitoshi Aibara, Tetsuro Yoshimaru, 尾野 雅哉, 笹 三徳, 三好 康雄 and Toyomasa Katagiri :
ミトコンドリアBIG3-PHB2 複合体は,トリプルネガティブ乳癌細胞の脆弱性を示す選択的治療標的である,
第81回日本癌学会学術総会, Oct. 2022.
6. Abdullah S. Ili, Tetsuro Yoshimaru, Yosuke Matsushita, Masato Komatsu, Miyoshi Yasuo, Honda Junko, Ohsumi Shozo, Sasa Mitsunori and Toyomasa Katagiri :
Whole-exome sequencing for the identification of Japanese familial breast cancer susceptibility genes,
The 81st Annual Meeting of the Japanese Cancer Association, Oct. 2022.
7. Yosuke Matsushita, Kazumasa Okumura, Masato Komatsu, Tetsuro Yoshimaru, 尾野 雅哉, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
トリプルネガティブ乳癌におけるRHBDL2 のグルタミン代謝調節機構,
第81回日本癌学会学術総会, Oct. 2022.
8. Tetsuro Yoshimaru, Yosuke Matsushita, 笹 三徳, 三好 康雄 and Toyomasa Katagiri :
細胞膜BIG3-PHB2 複合体がHER2 陽性乳癌のトラスツズマブ耐性 獲得に必須である,
第81回日本癌学会学術総会, Oct. 2022.
9. 加藤 廉平, 前川 滋克, 加藤 陽一郎, 兼平 貢, 高田 亮, Yosuke Matsushita, Tetsuro Yoshimaru, Tomoya Fukawa, Toyomasa Katagiri and 小原 航 :
3 次元培養下における新規の癌特異分子PRELID2 の分子機能の解明,
第81回日本癌学会学術総会, Oct. 2022.
10. Keiji Uchiyama, Tetsuro Yoshimaru, Yosuke Matsushita, 尾野 雅哉, 笹 三徳, 三好 康雄 and Toyomasa Katagiri :
乳がん細胞におけるO 結合型糖転移酵素の発現亢進はIRE1 の恒常的活性化を惹起する,
第81回日本癌学会学術総会, Sep. 2022.
11. Hitoshi Aibara, Tetsuro Yoshimaru and Toyomasa Katagiri :
ミトコンドリアBIG3-PHB2複合体ネットワークの脆弱性を標的としたトリプルネガティブ乳癌治療法の開発...,
第26回日本がん分子標的治療学会学術集会, Jul. 2022.
12. Yosuke Matsushita, Tetsuro Yoshimaru and Toyomasa Katagiri :
トリプルネガティブ乳癌におけるRHBDL2のグルタミン代謝調節機構の解明,
第26回日本がん分子標的治療学会学術集会, Jul. 2022.
13. Tetsuro Yoshimaru, Yosuke Matsushita and Toyomasa Katagiri :
トラスツズマブ耐性HER2陽性乳がんの克服に向けたBIG3-PHB2相互作用を標的とした持続型阻害ペプチドの開発,
第26回日本がん分子標的治療学会学術集会, Jul. 2022.
14. HAGIWARA Kosei, Keiji Uchiyama, Tetsuro Yoshimaru, Yosuke Matsushita and Toyomasa Katagiri :
乳がん細胞におけるO結合型糖鎖修飾GRP78/Bipの役割解明と創薬研究,
第26回日本がん分子標的治療学会学術集会, Jun. 2022.
15. Keiji Uchiyama, Yosuke Matsushita, Tetsuro Yoshimaru, HAGIWARA Kosei and Toyomasa Katagiri :
乳がん細胞におけるO型糖鎖修飾IRE1経路の恒常的活性化を標的とした新規治療戦略の可能性,
第26回日本がん分子標的治療学会学術集会, Jun. 2022.
16. Hitoshi Aibara, Tetsuro Yoshimaru, 尾野 雅哉, 笹 三徳, 三好 康雄 and Toyomasa Katagiri :
トリプルネガティブ乳癌細胞のミトコンドリア構造・機能制御におけるBIG3-PHB2複 合体の病態生理的役割-癌細胞の脆弱性を標的とした治療法開発,
第44回日本分子生物学会年会, Dec. 2021.
17. 松崎 淳平, 田代 伸也, 新田 莉彩子, 尾野 雅哉, Tetsuro Yoshimaru, Toyomasa Katagiri and 田村 康 :
]Split-TurboID-GFPを用いたヒトミトコンドリア-小胞体間コンタクトサイト局在化タン パク質の同定,
第44回日本分子生物学会年会, Dec. 2021.
18. 高橋 賢司, 田代 伸也, 尾野 雅哉, Tetsuro Yoshimaru, Toyomasa Katagiri and 田村 康 :
小胞体-リソソーム間コンタクトサイト局在タンパク質の同定,
第44回日本分子生物学会年会, Dec. 2021.
19. 藤本 慎太郎, 尾野 雅哉, Tetsuro Yoshimaru, Toyomasa Katagiri and 田村 康 :
出芽酵母におけるミトコンドリア-液胞膜間コンタクトサイト局在タンパク質の同定,
第44回日本分子生物学会年会, Dec. 2021.
20. Yosuke Matsushita, 高橋 定子, Masato Komatsu, Kazuma Kiyotani, Tetsuro Yoshimaru, 三好 康雄, 本田 純子, 紺谷 桂一, 大住 省三, 笹 三徳 and Toyomasa Katagiri :
日本人家族性乳癌家系の新規感受性遺伝子の解析,
日本人類遺伝学会第66回大会 第28回日本遺伝子診断学会大会 合同開催, Oct. 2021.
21. Hitoshi Aibara, Tetsuro Yoshimaru, 尾野 雅哉, 笹 三徳, 三好 康雄 and Toyomasa Katagiri :
ミトコンドリアBIG3-PHB2複合体の脆弱性を標的にしたトリプルネガティブ乳癌治療法の可能性考察,
第80回日本癌学会学術総会, Oct. 2021.
22. Tetsuro Yoshimaru, Srinivasan Yuvaraj, Hitoshi Aibara and Toyomasa Katagiri :
Disruption of BIG3-PHB2 complex suppresses the proliferation of non-small cell lung cancer.,
第80回日本癌学会学術総会, Oct. 2021.
23. Tetsuro Yoshimaru, Yosuke Matsushita, 笹 三徳, 三好 康雄 and Toyomasa Katagiri :
HER2陽性乳癌のトラスツズマブ耐性獲得に対するBIG3-PHB2複合体の病態生理学的役割,
第80回日本癌学会学術総会, Oct. 2021.
24. Yosuke Matsushita, Masato Komatsu, Kazuma Kiyotani, 新沼 猛, 鈴木 拓, Tetsuro Yoshimaru, 田嶋 敦, Issei Imoto, 本田 純子, 古川 洋一, 中村 祐輔, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
SALL3のエピゲノム異常はトリプルネガティブ乳癌の薬剤抵抗性の一因となる,
第80回日本癌学会学術総会, Oct. 2021.
25. Yutaka Kohmura, Daishiroh Kobayashi, 杉木 俊彦, Tetsuro Yoshimaru, Eisuke Kuraoka, Masaya Denda, 藤原 敏道, Toyomasa Katagiri and Akira Otaka :
Cys-Trp 架橋型乳がん抑制ペプチド(ERAP)の合成及び活性評価,
創薬懇話会2021 in 京都, Jun. 2021.
26. Tetsuro Yoshimaru, Yosuke Matsushita and Toyomasa Katagiri :
トラスツズマブ耐性HER2陽性乳がんに対するBIG3-PHB2相互作用の標的治療薬としての可能性,
第25回日本がん分子標的治療学会学術集会, May 2021.
27. Yosuke Matsushita, Masato Komatsu, Kazuma Kiyotani, 鈴木 拓, Tetsuro Yoshimaru, Issei Imoto and Toyomasa Katagiri :
新規がん抑制因子SALL3不活化はトリプルネガティブ乳癌の化学療法抵抗性に関与する,
第25回日本がん分子標的治療学会学術集会, May 2021.
28. Hitoshi Aibara, Tetsuro Yoshimaru and Toyomasa Katagiri :
トリプルネガティブ乳癌細胞においてBIG3-PHB2複合体は癌病態ミトコンドリアを安定制御する,
第25回日本がん分子標的治療学会学術集会, May 2021.
29. Hitoshi Aibara, Tetsuro Yoshimaru, 尾野 雅哉, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
トリプルネガティブ乳がん細胞におけるBIG3-PHB2複合体によるミトコンドリア構造・機能制御についての解析,
第43回日本分子生物学会年会, Dec. 2020.
30. Shun-ichi Toki, Tetsuro Yoshimaru, Hitoshi Aibara, Yosuke Matsushita and Toyomasa Katagiri :
ミトコンドリア局在BIG3-PHB2複合体の抑制は骨肉腫細胞の悪性化を阻害する,
第24回日本がん分子標的治療学会学術集会, Oct. 2020.
31. Hitoshi Aibara, Tetsuro Yoshimaru and Toyomasa Katagiri :
トリプルネガティブ乳癌細胞のミトコンドリア構造・機能制御におけるBIG3-PHB2複合体の病態生理的役割と創薬開発,
第24回日本がん分子標的治療学会学術集会, Oct. 2020.
32. Yosuke Matsushita, Tetsuro Yoshimaru and Toyomasa Katagiri :
トリプルネガティブ乳癌におけるRHBDL2のグルタミン代謝制御の役割解明,
第24回日本がん分子標的治療学会学術集会, Oct. 2020.
33. Tetsuro Yoshimaru, Yosuke Matsushita and Toyomasa Katagiri :
BIG3-PHB2標的治療薬によるトラスツズマブ耐性HER2陽性乳がんの克服,
第24回日本がん分子標的治療学会学術集会, Oct. 2020.
34. Toyomasa Katagiri, Tetsuro Yoshimaru and Yosuke Matsushita :
乳がん治療耐性克服を目指した抑制因子活性化誘導PPI阻害ペプチドの開発,
第24回日本がん分子標的治療学会学術集会, Oct. 2020.
35. Hitoshi Aibara, Tetsuro Yoshimaru, 尾野 雅哉, 笹 三徳, 三好 康雄 and Toyomasa Katagiri :
トリプルネガティブ乳癌細胞のミトコンドリア構造・機能制御におけるBIG3-PHB2複合体の病態生理的役割と創薬開発,
第79回日本癌学会学術総会, Oct. 2020.
36. Yosuke Matsushita, Masato Komatsu, Kazuma Kiyotani, Tetsuro Yoshimaru, 新沼 猛, 鈴木 拓, 本田 純子, Issei Imoto, Akira Tangoku, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
新規癌抑制遺伝子SALL3はトリプルネガティブ乳癌の薬剤抵抗性に関与する,
第79回日本癌学会学術総会, Oct. 2020.
37. Tetsuro Yoshimaru, Yosuke Matsushita, 尾野 雅哉, 笹 三徳, 三好 康雄 and Toyomasa Katagiri :
BIG3-PHB2複合体の形成が,HER2陽性乳癌のトラスツズマブ耐性獲得を誘導する,
第79回日本癌学会学術総会, Oct. 2020.
38. Shun-ichi Toki, Tetsuro Yoshimaru, Hitoshi Aibara, Yosuke Matsushita, 尾野 雅哉 and Toyomasa Katagiri :
ミトコンドリアBIG3-PHB2複合体阻害は骨肉腫の悪性化を抑制する,
第79回日本癌学会学術総会, Oct. 2020.
39. Shun-ichi Toki, Tetsuro Yoshimaru, Hitoshi Aibara, Yosuke Matsushita and Toyomasa Katagiri :
ミトコンドリア局在BIG3-PHB2複合体の機能抑制は骨肉腫細胞の悪性化を阻害する,
第35回日本整形外科学会基礎学術集会, Oct. 2020.
40. Shun-ichi Toki, Tetsuro Yoshimaru, Hitoshi Aibara, Yosuke Matsushita, Koichi Sairyo and Toyomasa Katagiri :
骨肉腫細胞悪性化におけるBIG3の役割解明と分子間相互作用阻害ペプチド薬による抗腫瘍効果,
第93回日本整形外科学会学術総会, Jun. 2020.
41. Keitaroh Anyohji, Keisuke Aihara, Tetsuro Yoshimaru, Yusuke Nishikawa, Masato Komatsu, Akira Shigenaga, Toyomasa Katagiri and Akira Otaka :
乳がん細胞におけるBIG3-PHB2相互作用を標的とした高持続性架橋ペプチドの開発,
日本薬学会第140年会, Mar. 2020.
42. Yosuke Matsushita, Masato Komatsu, Kazuma Kiyotani, Tetsuro Yoshimaru, 新沼 猛, 鈴木 拓, Junko Honda, Issei Imoto, Akira Tangoku, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
トリプルネガティブ乳癌の薬剤抵抗性に関与する新規癌抑制遺伝子SALL3の分子機構解明,
第1回日本癌学会若手の会, Feb. 2020.
43. Yosuke Matsushita, 高橋 定子, Masato Komatsu, Kazuma Kiyotani, Tetsuro Yoshimaru, 三好 康雄, Junko Honda, 粕谷 桂一, 大住 省三, 笹 三徳 and Toyomasa Katagiri :
全エキソーム解析による日本人家族性乳がん家系の新規感受性遺伝子の探索,
日本人類遺伝学会第64回大会, Nov. 2019.
44. Hitoshi Aibara, Tetsuro Yoshimaru, 尾野 雅哉, 笹 三徳, 三好 康雄 and Toyomasa Katagiri :
TNBC細胞のミトコンドリア制御における乳癌特異的分子BIG3の役割,
第78回日本癌学会学術総会, Sep. 2019.
45. Tetsuro Yoshimaru, Yosuke Matsushita, 笹 三徳, 三好 康雄 and Toyomasa Katagiri :
トラスツズマブ耐性乳がんに関連したBIG3-PHB2相互作用標的治療薬の開発,
第78回日本癌学会学術総会, Sep. 2019.
46. 加藤 廉平, Tomoya Fukawa, Yosuke Matsushita, Tetsuro Yoshimaru, 尾野 雅哉, Kei Daizumoto, 加藤 陽一郎, 小原 航 and Toyomasa Katagiri :
腎癌の癌化におけるPRELID2によるミトコンドリアROS制御機構の解明,
第78回日本癌学会学術総会, Sep. 2019.
47. Shun-ichi Toki, Tetsuro Yoshimaru, Yosuke Matsushita, Hitoshi Aibara and Toyomasa Katagiri :
骨肉腫細胞悪性化におけるBIG3の役割解明と分子間相互作用阻害ペプチド薬による抗腫瘍効果,
第78回日本癌学会学術総会, Sep. 2019.
48. Yosuke Matsushita, Kazumasa Okumura, Masato Komatsu, Ryuichiro Kimura, Tetsuro Yoshimaru, 尾野 雅哉, Junko Honda, Akira Tangoku, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
RHBDL2によるグルタミノリシスの制御はTNBCの悪性化や抗癌剤抵抗性に関連する,
第78回日本癌学会学術総会, Sep. 2019.
49. Keitaroh Anyohji, Keisuke Aihara, Tetsuro Yoshimaru, Akira Shigenaga, Toyomasa Katagiri and Akira Otaka :
がん抑制因子PHB2の部分配列を基盤とした乳がん阻害ペプチドの開発,
創薬懇話会2019 in 秋保, Jun. 2019.
50. Yosuke Matsushita, Masato Komatsu, Tetsuro Yoshimaru, 井本 逸成, 鈴木 拓 and Toyomasa Katagiri :
トリプルネガティブ乳癌におけるがん抑制因子SALL3の不活化機構の解明,
第23回日本がん分子標的治療学会学術集会, Jun. 2019.
51. Tetsuro Yoshimaru, Yosuke Matsushita and Toyomasa Katagiri :
BIG3複合体によるがん抑制因子PHB2の不活制化を介したトラスツズマブ耐性乳がんの増殖機構と新規治療法,
第23回日本がん分子標的治療学会学術集会, Jun. 2019.
52. Shun-ichi Toki, Tetsuro Yoshimaru, Yosuke Matsushita and Toyomasa Katagiri :
骨肉腫細胞悪性化におけるBIG3の役割解明と分子間相互作用阻害ペプチド薬による抗腫瘍効果の検討,
第23回日本がん分子標的治療学会学術集会, Jun. 2019.
53. Keitaroh Anyohji, Keisuke Aihara, Tetsuro Yoshimaru, Akira Shigenaga, Toyomasa Katagiri and Akira Otaka :
がん抑制タンパク質PHB2を基盤とした新規創薬シーズの開発,
日本薬学会第139年会, Mar. 2019.
54. Tetsuro Yoshimaru, Yosuke Matsushita and Toyomasa Katagiri :
新規Aキナーゼアンカータンパク質BIG3による抑制因子PHB2の制御はHER2乳癌細胞増殖に必須である,
第41回日本分子生物学会年会, Nov. 2018.
55. 高橋 定子, Yosuke Matsushita, Masato Komatsu, Kazuma Kiyotani, Tetsuro Yoshimaru, 本田 純子, 大住 省三, 笹 三徳 and Toyomasa Katagiri :
Identification and evaluation of novel susceptibility genes in Japanese familial breast cancer by whole exome sequencing,
第77回日本癌学会学術総会, Sep. 2018.
56. 加藤 廉平, Tomoya Fukawa, Tetsuro Yoshimaru, Yosuke Matsushita, 尾野 雅哉, Kei Daizumoto, 加藤 陽一郎, 小原 航 and Toyomasa Katagiri :
Critical roles of mitochondrial PRELID2 for renal carcinogenesis,
第77回日本癌学会学術総会, Sep. 2018.
57. Yosuke Matsushita, Masato Komatsu, Kazuma Kiyotani, Tetsuro Yoshimaru, 新沼 猛, 鈴木 拓, 本田 純子, Issei Imoto, Akira Tangoku, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
Downregulation of SALL3 by recurrent genetic and epigenetic alterations is involved in triple negative breast cancers,
第77回日本癌学会学術総会, Sep. 2018.
58. Kei Daizumoto, Tetsuro Yoshimaru, Yosuke Matsushita, Tomoya Fukawa, Hisanori Uehara, 尾野 雅哉, Masato Komatsu, Hiro-omi Kanayama and Toyomasa Katagiri :
Crucial roles of DDX31 as related to the status of TP53 in bladder cancer progression,
第77回日本癌学会学術総会, Sep. 2018.
59. Tetsuro Yoshimaru, Yosuke Matsushita, 笹 三徳, 三好 康雄 and Toyomasa Katagiri :
BIG3-PKA-PP1Cα複合体による癌抑制因子PHB2不活性化を介したトラスツズマブ耐性乳癌増殖機構と新規治療法開発,
第77回日本癌学会学術総会, Sep. 2018.
60. Kazumasa Okumura, Yosuke Matsushita, Masato Komatsu, Ryuichiro Kimura, Tetsuro Yoshimaru, 尾野 雅哉, 三好 康雄, Junko Honda, 笹 三徳, Akira Tangoku and Toyomasa Katagiri :
Ritical pathophysiological roles of a potential therapeutic target RHBDL2 in triple negative breast cancer,
第77回日本癌学会学術総会, Sep. 2018.
61. Keitaroh Anyohji, Keisuke Aihara, Tetsuro Yoshimaru, Akira Shigenaga, Toyomasa Katagiri and Akira Otaka :
がん 抑制タンパク質PHB2からの創薬シード発掘,
第50回若手ペプチド夏の勉強会, Aug. 2018.
62. Yosuke Matsushita, Masato Komatsu, Tetsuro Yoshimaru and Toyomasa Katagiri :
トリプルネガティブ乳がんの悪性化におけるRHBDL2の役割解明と創薬開発,
第22回日本がん分子標的治療学会学術集会, May 2018.
63. Yosuke Matsushita, Masato Komatsu, Kazuma Kiyotani, Tetsuro Yoshimaru, 宮川 義仁, 本田 純子, Issei Imoto, Akira Tangoku, 鈴木 拓, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
Identification of recurrent genetic and epigenetic alterations in triple negative breast,
日本人類遺伝学会 第62回大会, Nov. 2017.
64. Tetsuro Yoshimaru, 尾野 雅哉, Yosuke Matsushita, Masato Komatsu, 笹 三徳, 三好 康雄 and Toyomasa Katagiri :
BIG3-PKA-PP1Cα複合体による癌抑制因子PHB2不活性化を介したエストロゲン依存性乳癌増殖機構と新規治療法開発,
第76回日本癌学会学術総会, Sep. 2017.
65. 高橋 定子, Yosuke Matsushita, Masato Komatsu, Tetsuro Yoshimaru, 本田 純子, 大住 省三, 三木 義男, Issei Imoto, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
日本人家族性乳がん家系の全エキソーム解析による新規家族性乳がん感受性遺伝子の同定,
第76回日本癌学会学術総会, Sep. 2017.
66. Yosuke Matsushita, Masato Komatsu, Kazuma Kiyotani, Tetsuro Yoshimaru, 宮川 義仁, 本田 純子, Issei Imoto, Akira Tangoku, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
TNBCにおける包括的なゲノム解析によるZNFタンパク質のジェネティックかつエピジェネティックな変化の同定,
第76回日本癌学会学術総会, Sep. 2017.
67. 大豆本 圭, Tetsuro Yoshimaru, Tomoya Fukawa, Hisanori Uehara, 尾野 雅哉, Masato Komatsu, Hiro-omi Kanayama and Toyomasa Katagiri :
筋層浸潤性膀胱癌の多段階進展機構におけるDDX31, Mutant p53, EGFR Axisの役割解明,
第76回日本癌学会学術総会, Sep. 2017.
68. Kazumasa Okumura, Yosuke Matsushita, Masato Komatsu, Ryuichiro Kimura, Tetsuro Yoshimaru, 尾野 雅哉, 三好 康雄, Junko Honda, 笹 三徳, Akira Tangoku and Toyomasa Katagiri :
《Japanese Oral Sessions》トリプルネガティブ乳がんの悪性化におけるRHBDL2の役割解明,
第76回日本癌学会学術総会, Sep. 2017.
69. Ryuichiro Kimura, Taisuke Matsuo, 尾野 雅哉, Tetsuro Yoshimaru, Masato Komatsu, 本田 純子, 朴 在賢, 中村 祐輔, 笹 三徳, 三好 康雄 and Toyomasa Katagiri :
ムチン型糖転移酵素GALNT6はLGALS3BPの糖鎖修飾を通じて乳癌発症を制御する.,
第76回日本癌学会学術総会, Sep. 2017.
70. 加藤 廉平, Tomoya Fukawa, Tetsuro Yoshimaru, Yosuke Matsushita, 尾野 雅哉, 小原 航 and Toyomasa Katagiri :
腎癌の癌化におけるPRELID2の重要な役割,
第76回日本癌学会学術総会, Sep. 2017.
71. Tetsuro Yoshimaru, Yosuke Matsushita and Toyomasa Katagiri :
分子内架橋型BIG3-PHB2相互作用阻害ペプチドERAPによるホルモン依存性乳がん新規治療法の開発,
第21回日本がん分子標的治療学会学術集会, Jun. 2017.
72. Yosuke Matsushita, Masato Komatsu, Tetsuro Yoshimaru, 鈴木 拓, Issei Imoto and Toyomasa Katagiri :
全エクソームシーケンス解析によるトリプルネガティブ乳癌の分子特性の解明,
第21回日本がん分子標的治療学会学術集会, Jun. 2017.
73. Keisuke Aihara, Tetsuro Yoshimaru, Masato Komatsu, Akira Shigenaga, Toyomasa Katagiri and Akira Otaka :
Development of stapled peptides targeting BIG3-PHB2 interaction in breast cancer cells,
第53回ペプチド討論会, Oct. 2016.
74. Ryuichiro Kimura, 尾野 雅哉, Taisuke Matsuo, Tetsuro Yoshimaru, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
糖転移酵素GALNT6はガレクチン結合タンパク質1を糖鎖修飾し,乳癌発症を制御する,
第75回日本癌学会学術総会, Oct. 2016.
75. Tetsuro Yoshimaru, Yosuke Matsushita, Masato Komatsu, 岡崎 泰昌, 豊國 伸哉, 笹 三徳, 三好 康雄 and Toyomasa Katagiri :
内分泌療法耐性乳がんに対するBIG3-PHB2相互作用阻害ペプチドの開発,
第75回日本癌学会学術総会, Oct. 2016.
76. 瀧 亮祐, Tetsuro Yoshimaru, 大豆本 圭, Yosuke Matsushita, Ryuichiro Kimura, 尾野 雅哉 and Toyomasa Katagiri :
BIG3-PHB2相互作用を標的とした前立腺がん治療法の開発の可能性,
第75回日本癌学会学術総会, Oct. 2016.
77. Kazumasa Okumura, Masato Komatsu, Ryuichiro Kimura, 尾野 雅哉, Tetsuro Yoshimaru, Yosuke Matsushita, 三好 康雄, 本田 純子, 笹 三徳, Akira Tangoku and Toyomasa Katagiri :
トリプルネガティブ乳癌で高発現が認められるTNRHP1の発現亢進は癌の悪性度と相関する,
第75回日本癌学会学術総会, Oct. 2016.
78. Yosuke Matsushita, Masato Komatsu, Kazuma Kiyotani, Tetsuro Yoshimaru, 宮川 義仁, 本田 純子, Issei Imoto, Akira Tangoku, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
全エキソーム解析によるトリプルネガティブ乳癌の分子特性の解明,
第75回日本癌学会学術総会, Oct. 2016.
79. Tetsuro Yoshimaru, Masato Komatsu and Toyomasa Katagiri :
--,
第20回日本がん分子標的治療学会学術集会, Jun. 2016.
80. Namhee Kim, Tetsuro Yoshimaru, Toyomasa Katagiri and Eiji Tanaka :
乳がん細胞におけるがん抑制分子PHB2のエストロゲン依存性核内移行機序の解明,
第74回日本矯正歯科学会大会プログラム・抄録集, 194, Nov. 2015.
81. Toyomasa Katagiri, Masato Komatsu, Kazuma Kiyotani, Tetsuro Yoshimaru, Issei Imoto, 笹 三徳 and 三好 康雄 :
トリプルネガティブ乳癌における癌抑制遺伝子ZNFXの同定と不活化機構の解明,
日本人類遺伝学会第60会大会, Oct. 2015.
82. 大豆本 圭, Masato Komatsu, Ryuichiro Kimura, Tetsuro Yoshimaru, Hisanori Uehara, 尾野 雅哉, Tomoya Fukawa, Hiro-omi Kanayama and Toyomasa Katagiri :
P53変異型膀胱癌におけるDEAD box polypeptide31(DDX31)の機能解明,
第74回日本癌学会学術総会, Oct. 2015.
83. 宮川 義仁, Masato Komatsu, Kazuma Kiyotani, Tetsuro Yoshimaru, 本田 純子, 笹 三徳, 三好 康雄 and Toyomasa Katagiri :
トリプルネガティブ乳癌における癌抑制遺伝子BCLR1の発現低下について,
第74回日本癌学会学術総会, Oct. 2015.
84. Tetsuro Yoshimaru, Masato Komatsu, 田代 悦, 長田 裕之, 井本 正哉, 豊國 伸哉, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
エストロゲン受容体制御分子BIG3を標的とした新規ER陽性乳がんの治療法,
第74回日本癌学会学術総会, Oct. 2015.
85. Tetsuro Yoshimaru, Masato Komatsu, 田代 悦, 長田 裕之, 井本 正哉 and Toyomasa Katagiri :
エストロゲン受容体制御分子BIG3を標的とした新規ER陽性乳がん治療法の開発,
日本がん分子標的治療学会第19回学術集会, Jun. 2015.
86. Masato Komatsu, Tetsuro Yoshimaru, Issei Imoto and Toyomasa Katagiri :
トリプルネガティブ乳癌における新規腫瘍抑制遺伝子Zing finger protein-X(ZNFX)の不活化機構の解明,
日本がん分子標的治療学会第19回学術集会, Jun. 2015.
87. 大豆本 圭, Masato Komatsu, Tetsuro Yoshimaru, Hiro-omi Kanayama and Toyomasa Katagiri :
膀胱癌悪性化規定因子である新規核小体蛋白質DDX31の機能解析,
日本がん分子標的治療学会第19回学術集会, Jun. 2015.
88. Toyomasa Katagiri, Tetsuro Yoshimaru, Masato Komatsu, 田代 悦, 井本 正哉 and 長田 裕之 :
エストロゲン受容体制御分子BIG3を標的とした新規ホルモン依存性乳がん治療法の開発,
日本農芸化学会 2015年度(平成27年度)大会, Mar. 2015.
89. Toyomasa Katagiri, Tetsuro Yoshimaru and Masato Komatsu :
新規エストロゲンシグナル制御分子BIG3による新たながん抑制因子prohibitin2の機能喪失機構の解明,
第87回日本生化学学会大会, Oct. 2014.
90. 宮川 義仁, Masato Komatsu, Kazuma Kiyotani, Tetsuro Yoshimaru, 笹 三徳, 三好 康雄 and Toyomasa Katagiri :
トリブルネガティブ乳癌における癌抑制遺伝子BCLR1の発現低下について,
第73回日本癌学会学術総会, Sep. 2014.
91. Namhee Kim, Tetsuro Yoshimaru, Masato Komatsu, Taisuke Matsuo, 笹 三徳 and Toyomasa Katagiri :
乳癌細胞における癌抑制分子PHB2のエストロゲン依存性核内移行機構の解明,
第73回日本癌学会学術総会, Sep. 2014.
92. Masato Komatsu, Tetsuro Yoshimaru, 尾野 雅哉, Taisuke Matsuo, Kazuma Kiyotani, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
悪性度の高いトリプルネガティブ乳癌における核内19S-proteasome関連遺伝子(nPAG1)の役割,
第73回日本癌学会学術総会, Sep. 2014.
93. Tetsuro Yoshimaru, Masato Komatsu, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
エストロゲン受容体制御分子BIG3を標的とした新規ER陽性乳がん治療法の開発,
第73回日本癌学会学術総会, Sep. 2014.
94. 大豆本 圭, Masato Komatsu, Tetsuro Yoshimaru, Hisanori Uehara, Tomoya Fukawa, Hiro-omi Kanayama and Toyomasa Katagiri :
核小体がんタンパク質BCRG1は膀胱癌の進行に関連している,
第73回日本癌学会学術総会, Sep. 2014.
95. Masato Komatsu, Tetsuro Yoshimaru, Taisuke Matsuo and Toyomasa Katagiri :
トリプルネガティブ乳癌におけるプロテアソーム構成因子のプロテアソーム活性非依存的な役割,
第18回日本がん分子標的治療学会学術集会, Jun. 2014.
96. Tetsuro Yoshimaru, Masato Komatsu, Taisuke Matsuo and Toyomasa Katagiri :
エストロゲン受容体制御分子BIG3を標的とした新規ER陽性乳がんの治療法の創製,
第18回日本がん分子標的治療学会学術集会, Jun. 2014.
97. Tetsuro Yoshimaru, Masato Komatsu, Taisuke Matsuo, 三好 康雄, 笹 三徳, 中村 祐輔 and Toyomasa Katagiri :
エストロゲン受容体活性化制御分子ERAP1と腫瘍抑制因子REAの相互作用を標的とした内分泌療法耐性乳癌の治療法の開発,
72nd Annual Meeting of the Japanese Cancer Association72, Oct. 2013.
98. Taisuke Matsuo, Ono Masaya, Tetsuro Yoshimaru, Masato Komatsu, Miyoshi Yasuo, Sasa Mitsunori and Toyomasa Katagiri :
がん特異的糖転移酵素BCGT1による小胞体ストレス制御を介した新規乳癌細胞増殖機構の解明,
72nd Annual Meeting of the Japanese Cancer Association, Oct. 2013.
99. Yanai Ayako, Masato Komatsu, Tetsuro Yoshimaru, Kazuma Kiyotani, Ito Takashi, Hirota Seiichi, Sasa Mitsunori, Toyomasa Katagiri and Miyoshi Yasuo :
Molecular characteristics of ER-pisitive and HER2-negative breast cancer by immunohistochemistry,
72nd Annual Meeting of the Japanese Cancer Association, Oct. 2013.
100. Masato Komatsu, Tetsuro Yoshimaru, Taisuke Matsuo, Kazuma Kiyotani, Miyoshi Yasuo, Sasa Mitsunori and Toyomasa Katagiri :
Nuclear-19S proteasome associated gene 1 contributes to the aggressiveness of triple negative breast cancer cells,
72nd Annual Meeting of the Japanese Cancer Association, Oct. 2013.
101. Taisuke Matsuo, Tetsuro Yoshimaru and Toyomasa Katagiri :
新規糖転移酵素BCGT1による小胞体ストレス応答制御を介した乳癌細胞増殖機構の解明,
第17回日本がん分子標的治療学会学術集会, Jun. 2013.
102. Masato Komatsu, Tetsuro Yoshimaru, Taisuke Matsuo, Nakamura Yusuke and Toyomasa Katagiri :
ゲノムワイドな網羅的遺伝子発現情報解析を用いたトリプルネガティブ乳癌(TNBC)の分子特性および新たな治療標的の探索,
第17回日本がん分子標的治療学会学術集会, Jun. 2013.
103. Tetsuro Yoshimaru, Masato Komatsu, Taisuke Matsuo and Toyomasa Katagiri :
ERα活性化制御分子ERAP1を標的とした内分泌療法耐性乳癌の治療戦略,
第17回日本がん分子標的治療学会学術集会, Jun. 2013.
104. Masato Komatsu, Tetsuro Yoshimaru, Taisuke Matsuo, Kazuma Kiyotani, 柳井 亜矢子 and Toyomasa Katagiri :
トリプルネガティブ乳癌におけるプロテアソーム関連因子PAG1による新規増殖機構の解明,
第246回 徳島医学会学術集会(平成24年度冬期), Feb. 2013.
105. Kazuma Kiyotani, Fujimoto Akihiro, Masato Komatsu, Tetsuro Yoshimaru, Taisuke Matsuo, Tsunoda Tatsuhiko, Miyoshi Yasuo, Sasa Mitsunori and Toyomasa Katagiri :
Exome sequencing analysis of triple-negative breast cancer,
The 71th Annual Meeting of the Japanese Cancer Association, Sep. 2012.
106. Masato Komatsu, Tetsuro Yoshimaru, Taisuke Matsuo, Kazuma Kiyotani, Miyoshi Yasuo, Mitsuo Shimada, Nakamura Yusuke, Sasa Mitsunori and Toyomasa Katagiri :
Involvement of preteasome-associated gene 1(PAG1) in proliferation of triple negative breast cancer,
The 71th Annual Meeting of the Japanese Cancer Association, Sep. 2012.
107. Tetsuro Yoshimaru, Masato Komatsu, Taisuke Matsuo, Yasuo Miyoshi, Mitsunori Sasa, Yusuke Nakamura and Toyomasa Katagiri :
ERAP1 constitutively activates estrogen-signaling in ER-positive breast cancer by capturing intact tumor suppressor REA.,
The 71th Annual Meeting of the Japanese Cancer Association, Sep. 2012.
108. Toyomasa Katagiri, Tetsuro Yoshimaru, Taisuke Matsuo, Nakamura Yusuke, Miyoshi Yasuo and Sasa Mitsunori :
New insight into developing treatment stategies for breast cacer,
The 71th Annual Meeting of the Japanese Cancer Association, Sep. 2012.
109. Taisuke Matsuo, Ono Masaya, Tetsuro Yoshimaru, Miyoshi Yasuo, Sasa Mitsunori, Nakamura Yusuke and Toyomasa Katagiri :
Regulation of endoplasmic reticulum stress response by a novel glycosyltransferase BCGT1 in breast cancer progrression,
The 71th Annual Meeting of the Japanese Cancer Association, Sep. 2012.
110. Le T. Dat, Taisuke Matsuo, Tetsuro Yoshimaru, Souji Kakiuchi, Hisatsugu Goto, Kuramoto Takuya, Mitsuhashi Atsushi, Saburo Sone, Yasuhiko Nishioka and Toyomasa Katagiri :
LBMTF a novel transcriptional factor involved in lung cancer bone metastases,
The 71th Annual Meeting of the Japanese Cancer Association, Sep. 2012.
111. Masato Komatsu, Tetsuro Yoshimaru, Taisuke Matsuo, Kazuma Kiyotani, 三好 康雄, Mitsuo Shimada, 中村 祐輔, 笹 三徳 and Toyomasa Katagiri :
Involvement of proteasome-associated gene 1 (PAG1) in proliferation of triple negative breast cancer. (トリプルネガティブ乳癌におけるプロテアソーム関連遺伝子PAG1を介した発癌・増殖機構の関与),
第71回 日本癌学会学術総会, Sep. 2012.
112. Le T. Dat, Taisuke Matsuo, Tetsuro Yoshimaru, Takuya Kuramoto, Masaki Hanibuchi, Hisatsugu Goto, Souji Kakiuchi, Yasuhiko Nishioka, Saburo Sone and Toyomasa Katagiri :
Genome-wide gene expression profiling analysis of bone metastases of human non-smal cell lung cancer (NSCLC) in mice,
70th Annual Meeting of the Japanese Cancer Association, Oct. 2011.
113. Komatsu Masato, Tetsuro Yoshimaru, Taisuke Matsuo, Miyoshi Yasuo, Mitsuo Shimada, Nakamura Yusuke, Sasa Mitsunori, Miyano Satoru and Toyomasa Katagiri :
Novel therapeutic strategy for Triple Negative Breast Cancer,
Proceedings of the Japanese Cancer Association, 237, Oct. 2011.
114. 小松 正人, Tetsuro Yoshimaru, Taisuke Matsuo, 中村 祐輔 and Toyomasa Katagiri :
Triple negative breast cancer(TNBC)における新規増殖シグナル経路および治療標的分子同定の試み,
第15回日本がん分子標的治療学会学術集会, Jun. 2011.
115. Toyomasa Katagiri, Tetsuro Yoshimaru, Taisuke Matsuo, 三好 康雄, 笹 三徳 and 中村 祐輔 :
新規エストロゲン受容体活性化制御分子による乳癌細胞増殖機構の解明,
第11回ホルモンと癌研究会, Jul. 2010.
116. Tetsuro Yoshimaru, Taisuke Matsuo, Nakamura Yusuke and Toyomasa Katagiri :
新規エストロゲン受容体制御分子によるホルモン依存性乳がん増殖機構の解明,
第14回日本がん分子標的治療学会学術集会, Jul. 2010.
117. Masato Komatsu, Tetsuro Yoshimaru, Taisuke Matsuo and Toyomasa Katagiri :
--,
第18回日本がん分子標的治療学会学術集会, Jun. 2004.

Et cetera, Workshop:

1. Yosuke Matsushita, Masato Komatsu, Kazuma Kiyotani, Tetsuro Yoshimaru, 宮川 義仁, 本田 純子, Issei Imoto, Akira Tangoku, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
--,
第75回徳島乳腺研究会, Apr. 2016.
2. Ryuichiro Kimura, Tetsuro Yoshimaru, Masato Komatsu, 三好 康雄, 笹 三徳 and Toyomasa Katagiri :
トリプルネガティブ乳癌の発症・進展におけるBIG3の役割,
平成26年度がん若手研究者ワークショップ, Sep. 2014.
3. Tetsuro Yoshimaru, 石田 真由美 and Toyomasa Katagiri :
Elucidation of novel biological functions of Estrogen Receptor Activity-regulated Protein 1 in refractory breast cancer,
平成25年度がん若手研究者ワークショップ, Sep. 2013.
4. Masato Komatsu, Tetsuro Yoshimaru, Taisuke Matsuo, Kazuma Kiyotani, 斉藤 あゆむ, 山口 類, 宮野 悟, 三好 康雄, 笹 三徳, 中村 祐輔 and Toyomasa Katagiri :
Involvement of 26S proteasome-associated genes in carcinogenesis of triple negative breast cancer,
平成24年度がん若手研究者ワークショップ, Sep. 2012.
5. Taisuke Matsuo, 尾野 雅哉, Tetsuro Yoshimaru, 三好 康雄, 笹 三徳, 中村 祐輔 and Toyomasa Katagiri :
Identification of characterization of a novel glycosyltrasnferase BCGT1 involved in breast cancer cells,
平成23年度がん若手研究者ワークショップ, Sep. 2011.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

  • BIG3-PHB2 complexes is required for the acquired trastuzumab-resistance of HER2-positive breast cancer (Project/Area Number: 20K08958 )
  • Drug discovery in breast cancer utilizing reactivation of tumor suppressors (Project/Area Number: 17K19601 )
  • Acquired resistance to hormone therapy of breast cancer by mitochondrial reactive oxygen species (Project/Area Number: 17K10551 )
  • Clarification of novel pathophysiological roles of BIG3 in breast cancer cells (Project/Area Number: 16H05153 )
  • Therapeutic advances in BIG3-PHB2 inhibition targeting the cross-talk between estrogen and growth factors in breast cancer (Project/Area Number: 26461948 )
  • Drug development and biological function study of novel estrogen receptor activity modulator BIG3 protein (Project/Area Number: 25293079 )
  • 次世代シークエンサーによる新規乳がん関連遺伝子の探索 (Project/Area Number: 24501342 )
  • ミトコンドリア由来活性酸素を標的とした免疫難病治療の新戦略 (Project/Area Number: 21790293 )
  • Extracellular superoxide released from neutrophil is a critical determinant of severity of asthmatic symptoms : Role of Fcε I in asthmatic patient. (Project/Area Number: 19790696 )
  • Search by Researcher Number (80424729)